The Fund Grade · free · no account needed

What grade does PRHSX get?

Morningstar rates funds on what they returned. We grade them on where their money sits today: how much of the book overlaps with the converged buys of the top specialist stock pickers.

D

Fundprints Fund Grade · as of 2026-09-01

T. Rowe Price Health Sciences Fund

#283 of 440 graded active funds · blend · large segment peer group

The point · specialist footprint

PRHSX sits mid pack for specialist backing among graded funds.

Bottom 20%

Bottom 40%

● Middle

Top 40%

Top 20%

beat the S&P in 22% of quarters+3.8 pts/qtr better · 43% beat rate

The middle rungs sat between the extremes, and the pattern was monotonic: every step up in specialist backing came with better subsequent results. Not damning, not compelling. The fee decides whether it is worth it.

2,825 graded funds · 2.7 years of filings, measured as they were published · evidence, not advice

3 funds in the same segment carry an A — members see the names and what they charge. See the alternatives →

The grade scores this fund's specialist share — the slice that overlaps what the top 1% of proven funds are building. We ignore index ballast and names outside our edge on purpose: that slice is small, and it's what decides the outcome.

Conviction exposure

22.1%

of the book in specialist-converged names

Late-stage weight

25.3%

of the book in Crowded or Fading names

Active share

95.6%

how far it strays from the index

The best grades have beaten the worst by about +5% a year since we began grading. The gap held in 9 out of 10 months. Measured on filings as they were published, no hindsight.

Inside the book — top names by stage · as of 2026-09-09

Early Conviction
VRTX 2.4%ASND 1.4%BTSG 1%+9 locked
Consensus
LLY 10.1%TMO 4.1%MRK 3.4%+69 locked
Emerging
DHR 2%INSM 1.1%CELC 0.6%+10 locked
Crowded
UTHR 1.3%BSX 0.9%CVS 0.9%+10 locked
Fading
ISRG 3.7%SYK 3.5%ALNY 1.6%+24 locked

We email you the day it crosses 50% crowded, and where you stand every month.

Graded monthly from point-in-time filings. A description of where the money sits, not a recommendation. Evidence, not advice.

The read · what to do with it

Support leaving these positions

ISRG 3.7% of the fund · Fading

SYK 3.5% of the fund · Fading

ALNY 1.6% of the fund · Fading

UTHR 1.3% of the fund · Crowded

BSX 0.9% of the fund · Crowded

Where it's genuinely early

VRTX 2.4% of the fund · Early Conviction

DHR 2% of the fund · Emerging

ASND 1.4% of the fund · Early Conviction

Read from today's disclosed book. Evidence, not advice.

The evidence base updates this week.

The specialists — not the whales — are already positioned for what comes next. Stop finding out last.

Create your free account

No card required · open the feed in 30 seconds